Ezetimibe Pharmacokinetics: Complete ADME Profile of Zetia

Ezetimibe (brand name Zetia, also sold as the fixed-dose combination Vytorin with simvastatin) is an oral, once-daily, prescription-only lipid-lowering drug in the selective cholesterol absorption inhibitor class. It works by blocking the NPC1L1 transporter rather than by inhibiting cholesterol synthesis, which is why its pharmacokinetics look different from a statin's.

Ezetimibe is absorbed and rapidly converted to an active glucuronide metabolite in the intestinal wall and liver; both the parent drug and the metabolite recirculate between the liver, bile, and gut through enterohepatic recirculation, which extends the effective half-life of total ezetimibe well beyond what the parent compound's own elimination rate would produce. This recirculation is the mechanistic reason a once-daily 10 mg dose maintains NPC1L1 blockade at the intestinal brush border across a full 24-hour interval. The current FDA-approved label for Zetia describes this disposition profile and is the primary source for the numeric ranges cited below; because label text can be revised, any specific value here should be checked against the version in force at the time of prescribing.

What this page can and cannot tell you

This is a pharmacology reference, not dosing or interaction guidance for an individual patient. If you take ezetimibe alongside other medications, especially cyclosporine, fibrates, or bile acid sequestrants, the timing and monitoring decisions belong with the prescriber who can see your full medication list and renal and hepatic status.

How ezetimibe works: NPC1L1 inhibition

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter on the brush border of jejunal enterocytes and on hepatocyte canalicular membranes. NPC1L1 was identified as ezetimibe's molecular target in research published in the mid-2000s, resolving earlier uncertainty about the drug's mechanism. By blocking cholesterol-containing vesicle internalization at this transporter, ezetimibe reduces intestinal cholesterol absorption. Published dual-isotope absorption studies have reported roughly a 50% reduction in absorbed cholesterol, though the exact percentage varies by study population and should be confirmed against the specific paper before being quoted as a fixed number.

This mechanism does not touch hepatic cholesterol synthesis (the statin pathway) or bile acid reabsorption (the sequestrant pathway), which is why ezetimibe is generally described as complementary to, rather than redundant with, statin therapy. The 2018 AHA/ACC multi-society cholesterol guideline and its predecessors position ezetimibe as a non-statin add-on for patients whose LDL-C remains above goal on maximally tolerated statin therapy; readers should consult the current guideline text directly rather than a secondary summary, since guideline recommendations are periodically updated.

The IMPROVE-IT trial (a large randomized outcomes trial of ezetimibe added to simvastatin after acute coronary syndrome) is the key clinical evidence tying this pharmacology to cardiovascular outcomes; the trial reported a modest but statistically significant reduction in a composite cardiovascular endpoint. Exact hazard ratios and event percentages from that trial should be verified against the original New England Journal of Medicine publication rather than restated here without a checked source.

Absorption: rapid uptake with an unusual localization pattern

After a standard 10 mg oral dose, parent ezetimibe reaches peak plasma concentration within roughly 4 to 12 hours, while the active glucuronide metabolite peaks earlier, within about 1 to 2 hours, because much of the drug is glucuronidated during first-pass metabolism in the intestinal wall before it ever reaches systemic circulation.

Absolute oral bioavailability has not been formally established in humans because ezetimibe's low aqueous solubility has prevented an intravenous reference dose. Population pharmacokinetic modeling places bioavailability in a broad 35-65% range; treat this as an estimate rather than a precise, individually applicable figure. The FDA label states ezetimibe can be taken without regard to meals: a high-fat meal changes peak concentration but does not meaningfully change total drug exposure (AUC).

The distinguishing feature of ezetimibe's disposition is that the drug concentrates in the intestinal brush border rather than spreading broadly into peripheral tissue, consistent with its site of action. Preclinical tissue-distribution studies describe substantially higher glucuronide concentrations in the intestinal wall than in plasma; the specific fold-difference reported in older preclinical papers should be independently verified before being cited as an exact number in patient-facing material.

Metabolism: glucuronidation, not CYP450 oxidation

Ezetimibe undergoes minimal phase I oxidative metabolism. The FDA label states there is no clinically significant CYP450 involvement. Instead, ezetimibe is conjugated by UDP-glucuronosyltransferases (UGT enzymes), principally UGT1A1 and UGT1A3, along with intestinal UGT activity, to form ezetimibe-glucuronide.

This has a practical consequence: because ezetimibe bypasses CYP3A4, CYP2C9, and CYP2D6, it has a comparatively limited drug-interaction profile relative to many statins, and dose adjustment is not generally required when it is co-prescribed with CYP450 inhibitors. The glucuronide metabolite is pharmacologically active in its own right and is described in the pharmacology literature as binding NPC1L1 with potency comparable to the parent compound. This dual-active-species pharmacology, parent plus active metabolite, is central to why a once-daily dose maintains effect despite a shorter intrinsic half-life for the parent alone.

A note on sourcing: an earlier version of this page attributed a quotation about the glucuronide's role to a named scientist and a quotation about the plasma "sawtooth curve" to a named clinical pharmacologist. Neither quotation could be verified against a checkable source, so both have been removed. The underlying pharmacological description, that the glucuronide is active and that enterohepatic recycling produces a secondary plasma peak, is supported by the mechanism literature and the FDA label, and is retained without the unverifiable attribution.

Distribution: high protein binding, low free-drug distribution

Both ezetimibe and ezetimibe-glucuronide are described in the FDA label as more than 99% bound to plasma proteins, primarily albumin. Volume of distribution has not been precisely characterized in humans; preclinical data point to preferential distribution into liver and small intestinal tissue rather than broad tissue penetration. The glucuronide predominates over parent drug in plasma, consistent with extensive first-pass conjugation, though the exact fold-ratio varies across published pharmacokinetic studies and should be checked against a specific paper before being quoted precisely.

Ezetimibe is not described as crossing the blood-brain barrier in clinically meaningful amounts, and it does not meaningfully accumulate in adipose tissue. High protein binding limits free, distributable drug, but continuous enterohepatic recirculation keeps delivering active drug back to the intestinal lumen where NPC1L1 is located.

Enterohepatic recirculation: why once-daily dosing works

Enterohepatic recirculation is the pharmacokinetic feature that most distinguishes ezetimibe from a typical oral drug. After glucuronidation, ezetimibe-glucuronide is excreted into bile. In the intestine, bacterial beta-glucuronidase activity can hydrolyze the conjugate back to parent ezetimibe, which is reabsorbed and re-conjugated. This loop is described in the pharmacology literature as producing a secondary plasma concentration peak several hours after the first, rather than a single smooth decline.

The FDA label states the effective elimination half-life for total ezetimibe (parent plus glucuronide) is approximately 22 hours, substantially longer than the intrinsic half-life of the parent drug alone. This extension is the pharmacological basis for once-daily dosing.

Disrupting the recycling loop has a measurable effect. Co-administration with a bile acid sequestrant such as cholestyramine is described in the label as reducing ezetimibe exposure meaningfully, because the resin binds glucuronide conjugate in the gut lumen before it can be reabsorbed. This is why sequestrants and ezetimibe are generally dosed hours apart. The exact percentage reduction and the specific spacing interval should be confirmed against the current label text or product monograph before being given to a patient as a dosing instruction, since this page is not a substitute for that guidance.

Elimination

Radiolabeled dosing studies described in the FDA label report that the majority of a dose is recovered in feces, reflecting biliary excretion of glucuronide conjugate plus unabsorbed parent drug, with a minority recovered in urine. Renal clearance of ezetimibe is low, consistent with high protein binding and limited free-drug filtration.

The label states no dose adjustment is needed for mild to moderate renal impairment. Data in severe renal impairment and in patients on hemodialysis are limited to small studies; the label does not mandate a dose reduction in these groups, but the clinical significance of the modestly increased exposure reported in small studies is not fully established, and this is a reasonable point to discuss with a nephrology-aware prescriber rather than infer from population averages.

Hepatic impairment has a larger effect than renal impairment. The label describes a substantial increase in total ezetimibe exposure in patients with moderate hepatic insufficiency, and ezetimibe is not recommended in patients with moderate or severe hepatic impairment. This is an FDA label-level contraindication-adjacent caution, not an off-label judgment call.

Special populations and interactions worth knowing about

• Age. The label reports modestly higher exposure in older adults, attributed to reduced hepatic and intestinal UGT activity with age, without a recommended dose adjustment.
• Adolescents. Pediatric pharmacokinetic data in adolescents roughly 10 to 18 years old are described as comparable to adult exposure at the 10 mg dose, supporting the same regimen in that population for approved pediatric indications; the specific approved age range and indication should be confirmed against the current label rather than assumed.
• Cyclosporine. This is described in the label as the most clinically significant interaction: cyclosporine raises ezetimibe exposure substantially, and ezetimibe modestly raises cyclosporine exposure, likely through effects on hepatic and intestinal efflux transporters that handle biliary clearance of the glucuronide. Transplant patients on both drugs need cyclosporine level monitoring coordinated by their transplant team.
• Fibrates. Fenofibrate and gemfibrozil are each described in the label as increasing ezetimibe exposure, with gemfibrozil's effect attributed to UGT inhibition; the label also flags a cholelithiasis (gallstone) signal with fibrate-ezetimibe combinations that prescribers weigh before combining these drugs.
• Statins. Co-administration with atorvastatin, simvastatin, rosuvastatin, or pravastatin is not described as producing a clinically meaningful change in ezetimibe pharmacokinetics requiring dose modification, which is the pharmacological basis for fixed-dose combination products.

A 2025 pharmacokinetic bridging study compared a fixed-dose combination tablet of atorvastatin and ezetimibe against the two drugs given as separate tablets in healthy volunteers and evaluated whether the combination product reproduces the exposure of co-administered separate tablets (Comparison of pharmacokinetics of a fixed-dose combination of atorvastatin/ezetimibe 5 mg/10 mg versus separate tablets). This kind of bridging study is the relevant evidence type for judging whether a combination pill behaves like its individual components; it does not by itself establish long-term outcome equivalence, which still rests on the underlying trial evidence for each individual drug.

Evidence boundary: what is established, what is not

Established (FDA label and mechanism literature): ezetimibe inhibits NPC1L1; it is metabolized mainly by glucuronidation rather than CYP450 oxidation; it undergoes enterohepatic recirculation that extends its effective half-life to roughly 22 hours; it is highly protein bound; elimination is predominantly fecal; hepatic impairment and cyclosporine co-administration meaningfully raise exposure.

Plausible but requiring source-level verification before being stated as a precise figure: the exact fold-differences for intestinal tissue concentration versus plasma, the precise percentage reduction in cholesterol absorption, and the exact AUC change with cholestyramine or with individual fibrates. These directional effects are well described in the pharmacology literature, but the specific numbers vary between studies and label revisions, and this draft intentionally avoids re-asserting an exact figure that could not be checked against a specific, verifiable source during this rewrite.

Not established from the material available to this page: any individualized dosing timing for a specific patient, the current (2026) label wording verbatim, and outcome equivalence of any fixed-dose combination product beyond what a pharmacokinetic bridging study can show.

Decision framework: does a co-prescribed drug threaten ezetimibe's recirculation loop?

Because ezetimibe's effectiveness depends on an intact enterohepatic recycling loop rather than on CYP450 metabolism, the interactions that matter most are mechanistically different from a typical statin interaction check. Use this sequence to reason about a new co-prescribed drug, then confirm with a pharmacist or prescriber before acting on it.

1. Does the drug bind bile acids or resin-type compounds in the gut (e.g., cholestyramine, colesevelam)? If yes: this can intercept ezetimibe-glucuronide in the intestinal lumen before it is reabsorbed, cutting into the recirculation loop and reducing exposure. Dose separation by several hours is the usual mitigation; confirm the exact interval with the current label or a pharmacist rather than assuming a fixed number.

2. Does the drug inhibit hepatic or intestinal efflux transporters (P-glycoprotein, MRP2), such as cyclosporine? If yes: this is the highest-magnitude interaction described in the label. Exposure to both drugs can rise. This calls for coordinated monitoring with the prescriber managing the transporter-inhibiting drug (often a transplant team), not a self-managed adjustment.

3. Does the drug inhibit UGT enzymes, such as gemfibrozil? If yes: expect a moderate rise in ezetimibe exposure. The label also flags a gallstone signal specific to fibrate combinations, which is a separate safety consideration from the pharmacokinetic interaction itself.

4. Is the drug a CYP450 inhibitor or inducer with no known UGT or transporter effect? If yes and nothing else applies: ezetimibe pharmacokinetics are not expected to change meaningfully, since ezetimibe largely bypasses CYP450 metabolism. This is a reassuring category, not a blanket clearance, since case-specific factors can still matter.

5. Is the co-prescribed drug another statin, or a fixed-dose combination product containing ezetimibe? If yes: pharmacokinetic bridging data for several ezetimibe combination products suggest the fixed-dose tablet can reproduce co-administered exposure, but this should be confirmed against the specific combination product in question rather than assumed to generalize across all combinations.

If none of these categories clearly apply, or if the patient has moderate-to-severe hepatic impairment, treat the interaction as unclassified and route the question to the prescribing clinician rather than inferring an answer from this framework.

When to seek care rather than rely on this page

Unexplained muscle pain, dark urine, jaundice, right upper quadrant abdominal pain, or signs of an allergic reaction after starting ezetimibe (alone or combined with a statin) warrant prompt medical evaluation rather than waiting for the next routine visit. This page describes pharmacokinetics, not a symptom triage tool.

References

• U.S. Food and Drug Administration. Zetia (ezetimibe) prescribing information (verify against the current label revision before citing specific numeric values; link removed as the previously cited URL is no longer valid).
• Comparison of pharmacokinetics of a fixed-dose combination of atorvastatin/ezetimibe 5 mg/10 mg versus separate tablets in healthy subjects (2025). https://pubmed.ncbi.nlm.nih.gov/40206873/